MeiraGTx (MGTX) Chardan's 8th Annual Genetic Medicines Conference summary

Company overview and technology

• Focuses on genetic medicines for large indications using DNA, enabling control of mRNA production from any DNA template.

• Pipeline aims to deliver biologics or hormones via oral small molecules and DNA templates.

• All clinical programs to date have been successful, with robust in-house manufacturing and optimized vectors reducing costs and increasing scalability.

Key clinical programs and milestones

• XLRP program partnered with Johnson & Johnson, with Phase III data expected this year; design includes untreated and two dosing groups, with BCVA as the primary endpoint.

• LCA4 gene therapy showed all 11 treated children gained sight; received UK Innovation Passport and is pursuing marketing authorization under exceptional circumstances.

• Radiation-induced xerostomia program demonstrated transformational Phase I results, with a pivotal Phase II/III study ongoing and regulatory filing targeted for 2026.

• Parkinson's AAV-GAD program modifies brain circuitry, showing significant benefit on UPDRS against sham; bridging study data expected soon to support Phase III initiation.

Manufacturing and commercial strategy

• In-house GMP manufacturing supports clinical and commercial supply, with two facilities and global regulatory validation.

• Commercial manufacturing agreement in place for XLRP launch with Johnson & Johnson, providing revenue upside.

• Optimization of vectors and processes enables lower doses, reduced costs, and broader patient access.